Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2007

Asuragen Accesses Xenomic’s NPM1 Technology for Diagnostic Development

  • Xenomics granted Asuragen coexclusive, worldwide rights to incorporate NPM1 technology into Asuragen's molecular diagnostic products. Under the terms of this agreement, Asuragen will have the right to develop, manufacture, and market products for the diagnosis, stratification, and monitoring of patients with acute myeloid leukemia (AML).

    A recent discovery, for which Xenomics holds exclusive rights, showed that many AML patients have mutations in the nucleophosmin (NPM1) gene, a favorable marker for clinical outcome. It is hoped that the results of such a test will help physicians select patients with a good prognosis of benefiting from intensive chemotherapy.

    The NPM1 mutation may also be used to monitor AML patients for residual disease during chemotherapy.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »